Article
Medicine, General & Internal
Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Summary: This study evaluated the effectiveness and safety of GP2017, a biosimilar drug, in the treatment of inflammatory bowel disease (IBD). The results showed that GP2017 is an effective and safe therapy for IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Summary: This study assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs). The results showed that switching from intravenous to subcutaneous infliximab was safe and well accepted, with a low risk of relapse in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Lauranne A. A. P. Derikx, Heather W. Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S. Rees, Mathew Lyons, Spyros Siakavellas, Nathan Constantine-Cooke, Philip Jenkinson, Shanna Su, Claire O'Hare, Laura Kirckpatrick, Lynne M. Merchant, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees
Summary: The study found that switching from the ADA originator to SB5 is effective and safe for patients with inflammatory bowel disease. Over 12 months of follow-up, most patients remained stable on SB5 treatment. The most frequently reported adverse event was injection site pain.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Pediatrics
Ruth Garcia-Romero, Jose Miguel Martinez de Zabarte Fernandez, Gemma Pujol-Muncunill, Ester Donat-Aliaga, Oscar Segarra-Canton, Inaki Irastorza-Terradillos, Enrique Medina-Benitez, Carlos Jose Ruiz-Hernandez, Marta Carrillo-Palau, Ignacio Ros-Arnal, Alejandro Rodriguez-Martinez, Laura Escartin-Madurga, Carolina Gutierrez-Junquera, Saioa Vicente-Santamaria, Marta Velasco Rodriguez-Belvis, Sonia Fernandez-Fernandez, Jose Ramon Alberto-Alonso, Montserrat Montraveta, Ricardo Torres-Peral, Maria Navalon-Rubio, Victor Manuel Navas-Lopez, Javier Martin de Carpi
Summary: This study assessed the effectiveness and safety of Vedolizumab in children with inflammatory bowel disease, showing that it is a safe and effective option for achieving clinical remission in pediatric patients with primary failure or loss of response to other treatments, especially in UC. High clinical remission rates were observed in pediatric patients refractory to anti-TNF compared to those reported in adults, with few publications on pediatric populations treated with Vedolizumab and with long-term follow-up (52 weeks).
EUROPEAN JOURNAL OF PEDIATRICS
(2021)
Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Olga N. N. Lopez-Garcia, Cristina Alba
Summary: This study provides evidence on the real-world outcomes of ustekinumab for ulcerative colitis (UC) patients. The meta-analysis confirms the effectiveness of ustekinumab in achieving clinical remission and response in a highly treatment-refractory population of UC patients. The safety profile of ustekinumab is also demonstrated with low rates of adverse events and serious infections.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Article
Gastroenterology & Hepatology
Robert Gilmore, Wei Lian Tan, Richard Fernandes, Yoon-Kyo An, Jakob Begun
Summary: This study found that upadacitinib may be a safe and effective salvage therapy for patients with steroid-refractory acute severe ulcerative colitis who have previously failed to respond to infliximab therapy. Prospective studies are needed to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
A. Buisson, M. Nachury, M. Bazoge, C. Yzet, P. Wils, M. Dodel, D. Coban, B. Pereira, M. Fumery
Summary: Switching from intravenous to subcutaneous infliximab can reduce the long-term risk of relapse in patients with inflammatory bowel disease. Close monitoring and dose escalation should be recommended for patients receiving different doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein
Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Public, Environmental & Occupational Health
Ting Zhou, Yanan Sheng, Haijing Guan, Rui Meng, Zijing Wang
Summary: The study found that vedolizumab is a more cost-effective option compared to infliximab in the treatment of anti-TNF-alpha naive adult patients with moderate-to-severe active UC in China. Sensitivity analyses indicated that the annual discount rate and health-state costs had the greatest impact on the results.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Lu Liu, Dan Pu, Dandan Wang, Muhan Zhang, Chuan Zhou, Zhe Zhang, Baisui Feng
Summary: This study identified five DEPs as novel drug targets and predictive biomarkers for non-response to IFX, providing important insights into potential drug resistance mechanisms in UC patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Rahul S. Dalal, Emma L. McClure, Jenna Marcus, Jessica R. Allegretti
Summary: This study compared the long-term drug survival of vedolizumab, adalimumab, and infliximab in patients with ulcerative colitis (UC). The results showed that vedolizumab had better survival rates than adalimumab for both clinical response and adverse effects, and vedolizumab also had better survival rates than infliximab for adverse effects.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Review
Gastroenterology & Hepatology
Raseen Tariq, Tausif Syed, Devvrat Yadav, Larry J. Prokop, Siddharth Singh, Edward V. Loftus, Darrell S. Pardi, Sahil Khanna
Summary: Systematic review and meta-analysis showed that fecal microbiota transplantation (FMT) is a safe and effective therapy for recurrent Clostridioides difficile infection (CDI) in patients with underlying inflammatory bowel disease (IBD), with high cure rates and potential benefits for IBD outcomes.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Daniel C. Baumgart, Krisztina Gecse, Jami A. Kinnucan, Susan B. Connelly, Leonardo Salese, Chinyu Su, Kenneth K. Kwok, John C. Woolcott, Alessandro Armuzzi
Summary: CDIs in patients with UC receiving tofacitinib were infrequent, with mild-moderate severity, and most cases resolved with treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Quazim A. Alayo, Edward Loftus Jr, Andres Yarur, David Alvarado, Matthew A. Ciorba, Lisa de las Fuentes, Parakkal Deepak
Summary: Population-based studies have shown that patients with inflammatory bowel disease (IBD) have an increased risk of acute arterial events (AAEs). This study aimed to assess the risk of incident AAEs and premature AAEs in participants with IBD in the UK Biobank (UKB) and found that IBD patients had a higher risk of AAEs and premature AAEs compared to non-IBD controls.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zeinab Bakhshi, Siddhant Yadav, W. Scott Harmsen, Jithinraj Edakkanambeth Varayil, Kevin A. Karls, William J. Tremaine, Edward V. Loftus
Summary: Risk factors for osteonecrosis in inflammatory bowel disease patients include corticosteroid use, estrogen use, arthropathy, and osteoporosis.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Severine Vermeire, Brian G. Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi
Summary: In patients with ulcerative colitis, the study found that 200 mg of filgotinib can reduce the use of corticosteroids and maintain corticosteroid-free clinical remission. Moreover, compared to other medications, filgotinib demonstrated better outcomes in patients who had not previously used biologic agents.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Daniela Guerrero Vinsard, David H. Bruining, James E. East, Derek Ebner, Sunanda V. Kane, John B. Kisiel, Jonathan A. Leighton, Ryan J. Lennon, Edward V. Loftus, Talha Malik, Michael Picco, Laura Raffals, Guilherme P. Ramos, Priscila Santiago, Nayantara Coelho-Prabhu
Summary: This study aimed to determine the interobserver agreement and accuracy of endoscopists for pathology prediction of visible lesions in inflammatory bowel disease (IBD) using the modified Paris classification. The results showed very low agreement for both the Paris and modified Paris classifications, as well as low accuracy for pathology prediction.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Edward Loftus, Peter D. R. Higgins, James O. Lindsay, Wen Zhou, Xuan Yao, Dapo Ilo, Charles Phillips, Jacinda Tran, Yuri Sanchez Gonzalez, Severine Vermeire
Summary: The study evaluated the benefits of UPA on the HRQoL of patients with ulcerative colitis, and found that UPA treatment significantly improved patients' quality of life.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Gary R. Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T. Judd, Thomas Jones, Edward V. Loftus
Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Surgery
Amanda M. Johnson, Andrew C. Storm, Tala Mahmoud, Rabih Ghazi, Babusai Rapaka, Donna M. Abboud, Edward V. Loftus Jr, Barham K. Abu Dayyeh
Article
Medicine, Research & Experimental
Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
Summary: In patients with moderate to severe Crohn's disease (CD), intravenous induction and subcutaneous maintenance dosing with risankizumab was effective and well tolerated. Self-administration of risankizumab using an on-body injector (OBI) may improve treatment adherence and convenience for patients.
ADVANCES IN THERAPY
(2023)
Article
Gastroenterology & Hepatology
Jessica A. Ulrich, Nawras W. Habash, Yasmine A. Ismail, William J. Tremaine, Amy L. Weaver, Joseph A. Murray, Edward V. Loftus Jr, Imad Absah
Summary: This study compared the effectiveness of HBV vaccination for patients with IBD/CD and matched referents, and found that routine testing of anti-HBs titers may not be necessary for fully vaccinated patients with IBD/CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Reena Khanna, Christopher Ma, Malcolm Hogan, Guangyong Zou, Talat Bessissow, Brian Bressler, Jean-Frederic Colombel, Silvio Danese, Marco Daperno, James E. East, Lawrence Hookey, Edward V. Loftus Jr, John W. D. Mcdonald, Remo Panaccione, Laurent Peyrin-Biroulet, Matt Rutter, Bruce E. Sands, Serverine Vermerire, Julie Remillard, Stefanie C. McFarlane, William J. Sandborn, Geert R. D'Haens, Brian G. Feagan, Vipul Jairath
Summary: This study aimed to define appropriate items for evaluating endoscopic activity and conventions for consistent endoscopic scoring rules in Crohn's disease (CD). The results showed that ulcers, narrowing, and healing should be included in the endoscopic scoring, while scarring and inflammatory polyps should not. The optimal method for defining ulcer depth remains uncertain. This study identified priorities for future research to develop a more representative endoscopic index for CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Siri A. Urquhart, Bryce P. Comstock, Mauricio F. Jin, Courtney N. Day, John E. Eaton, William S. Harmsen, Laura E. Raffals, Edward Loftus, Nayantara Coelho-Prabhu
Summary: The incidence of pouch neoplasia in inflammatory bowel disease patients who have undergone ileal pouch-anal anastomosis (IPAA) is low. Extensive colitis, primary sclerosing cholangitis, and backwash ileitis prior to IPAA as well as rectal dysplasia at time of IPAA raise the risk of pouch neoplasia significantly.
INFLAMMATORY BOWEL DISEASES
(2023)
Editorial Material
Dermatology
Afsaneh Alavi, Edward V. Loftus Jr
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire
Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)